Treatment of Pre-Collapse Stages of Osteonecrosis of the Femoral Head: A Systematic Review of Randomized Control Trials

Background Treatment for osteonecrosis of the femoral head (ONFH) remains controversial. Current reviews include low-level evidence studies evaluating the treatment of both pre-collapse and collapse stages of the disease. Questions/Purposes The purpose of the current study is to systematically revie...

Full description

Saved in:
Bibliographic Details
Published in:HSS Journal 2016-10, Vol.12 (3), p.261-271
Main Authors: Villa, Jordan C., Husain, Solomon, van der List, Jelle P., Gianakos, Arianna, Lane, Joseph M.
Format: Article
Language:English
Subjects:
Anesthesiology
Imaging
Medicine
Medicine & Public Health
Orthopedics
Radiology
Review
Review Article
Rheumatology
Sports Medicine
Surgical Orthopedics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Treatment for osteonecrosis of the femoral head (ONFH) remains controversial. Current reviews include low-level evidence studies evaluating the treatment of both pre-collapse and collapse stages of the disease. Questions/Purposes The purpose of the current study is to systematically review the literature evaluating core decompression (CD) with bone marrow mesenchymal cells (BMMCs), CD alone, and bisphosphonate treatment in pre-collapse ONFH by focusing just on randomized clinical trials (RCTs) reporting functional and radiologic outcomes. We aim to determine if the literature provides evidence supporting any single approach. Methods Using PubMed and EMBASE databases, we reviewed the clinical evidence of treatments for pre-collapse ONFH following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Twelve RCTs met the inclusion criteria. Results Results showed that CD with BMMCs has lower risk of femoral head collapse when compared to the CD alone excluding hips lost to follow-up (relative risk (RR) [95% CI]:0.25 [0.11, 0.60]; p = 0.002) and when assumed that hips lost to follow-up experienced collapse (RR [95% CI]: 0.11 [0.03, 0.47]; p = 0.003). Neither CD nor bisphosphonate treatments showed lower risk to femoral head collapse when compared to control treatments (p = 0.46 and 0.31, respectively) Conclusion Current literature shows that there is a lower risk of femoral head collapse in patients with ONFH treated with CD combined with BMMCs when compared to CD alone; however, there is no robust evidence to determine the effect on functional outcomes. More RCTs assessing new combination therapies and using standardized outcome measures are required.
ISSN:1556-3316
1556-3324
DOI:10.1007/s11420-016-9505-9